The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Items</td><td class="align_center">Locally advanced ESCC patients (<i>N</i> = 25)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left" colspan="2"><i>Clinical response, no. (%)</i></td></tr><tr><td class="align_left">CR</td><td class="align_center">2 (8.0)</td></tr><tr><td class="align_left">PR</td><td class="align_center">14 (56.0)</td></tr><tr><td class="align_left">SD</td><td class="align_center">9 (36.0)</td></tr><tr><td class="align_left">PD</td><td class="align_center">0 (0.0)</td></tr><tr><td class="align_left" colspan="2"><hr/></td></tr><tr><td class="align_left" colspan="2"><i>ORR, no. (%)</i></td></tr><tr><td class="align_left">Yes</td><td class="align_center">16 (64.0)</td></tr><tr><td class="align_left">No</td><td class="align_center">9 (36.0)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>ESCC, esophageal squamous-cell carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response.<br/></div></td></tr></table>

<div>Clinical response after neoadjuvant treatment.</div>

Journal of Clinical Pharmacy and Therapeutics

tab2

Table 2

Table 2: The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma 

Table 2 | The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma 